Edition:
United Kingdom

Quotient Ltd (QTNT.OQ)

QTNT.OQ on NASDAQ Stock Exchange Global Market

4.37USD
7:28pm GMT
Change (% chg)

$-0.01 (-0.23%)
Prev Close
$4.38
Open
$4.40
Day's High
$4.50
Day's Low
$4.33
Volume
13,643
Avg. Vol
76,470
52-wk High
$7.72
52-wk Low
$3.22

Latest Key Developments (Source: Significant Developments)

Quotient Ltd qtrly loss per share $0.58​
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Quotient Ltd ::Quotient limited reports second quarter fiscal 2018 financial results.Sees fy 2018 revenue $25 million to $27 million.Quotient Ltd qtrly ‍total revenue $5.9 million versus $6.1 million​.Quotient Ltd qtrly loss per share $0.58​.  Full Article

Highbridge Capital Management reports 9.92 pct passive stake in Quotient Ltd
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Quotient Ltd :Highbridge Capital Management Llc reports 9.92 percent passive stake in Quotient Ltd as on October 24 - SEC filing.  Full Article

Quotient reports positive concordance data from Mosaiq platform
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Quotient Ltd :Quotient reports positive concordance data from Mosaiq verification and validation studies for blood grouping and announces financing.Announces sale of ordinary shares and warrants with initial proceeds of $40 million​.European field trials for Mosaiq platform planned to commence prior to year-end​.  Full Article

Quotient Limited announces $40 million private placement
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Quotient Ltd :Quotient Limited announces $40 million private placement and the issue of warrants to raise up to an additional $49 million.Intends to use proceeds from financing to fund ongoing development and if approved, commercialization of Mosaiq​.  Full Article

Quotient Limited reports Q1 loss per share $0.64
Monday, 8 Aug 2016 

Quotient Limited : Reports Further Progress On The Commercial Scale-Up of Mosaiq and first quarter fiscal 2017 financial results . Q1 loss per share $0.64 . Sees FY 2017 revenue $21.7 million to $22.7 million . Sees FY 2017 revenue up 17 to 23 percent . Quotient Ltd qtrly total revenue $5.7 million versus $4.9 million last year . Quotient Ltd sees fiscal year 2017 operating loss in range of $55.0 million to $60.0 million . Q1 earnings per share view $-0.68, revenue view $5.7 million -- Thomson Reuters I/B/E/S . Q1 revenue view $5.7 million -- Thomson Reuters I/B/E/S . Quotient Ltd sees fiscal year product sales of $19.0 million to $20.0 million . Quotient Ltd sees product sales in q2 of fiscal 2017 to be within range of $4.4 million to $4.9 million .FY2017 earnings per share view $-2.20, revenue view $20.8 million -- Thomson Reuters I/B/E/S.  Full Article

Quotient Limited prices offering 2.8 mln of ordinary shares
Friday, 29 Jul 2016 

Quotient Ltd : Quotient limited announces pricing of underwritten offering of ordinary shares .Public offering of 2.8 million of its ordinary shares at a price to public of $5.50 per share.  Full Article

Quotient expects qtrly total revenue and product sales to be about $5.7 mln
Monday, 11 Jul 2016 

Quotient Ltd : Quotient Limited provides update on the Mosaiq(tm) development plan and reports preliminary fiscal first quarter 2017 revenues . For three months ended June 30, 2016, quotient's total revenue and product sales are expected to be approximately $5.7 million . Product sales in q1 of fiscal 2017 were previously expected to be within range of $4.7 to $5.2 million, compared with $4.9 million in q1 . European field trials for mosaiq blood grouping consumable, initial mosaiq serological disease screening consumable now planned to start in nov . European field trials for mosaiq blood grouping consumable, initial mosaiq serological disease expected to be reported in q1 of calendar 2017 .Validation process also identified minor factory modification needed to control humidity levels during final assembly of mosaiq consumables.  Full Article

Quotient Ltd announces positive mosaiq serological disease screening results
Wednesday, 13 Apr 2016 

Quotient Ltd:Quotient Limited announces positive mosaiq serological disease screening results.Results of the validation studies exceeded company's internal performance targets.  Full Article

Quotient Ltd expects MosaiQ launch in Europe in Q4 2016
Monday, 11 Jan 2016 

Quotient Ltd:Announces positive serological disease screening results and provides Mosaiq(TM) development program update.Says expects to begin marketing Mosaiq(TM) in Europe during the fourth quarter of 2016.Says company anticipates commercial launch in the United States in the first quarter of 2018.Anticipates commercial launch of expanded Mosaiq(TM) disease screening consumable in Europe during H2 2017 and in U.S. in 2018.  Full Article

BRIEF-Quotient Ltd qtrly loss per share $0.58​

* Quotient limited reports second quarter fiscal 2018 financial results